<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03514420</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 703802-CS5</org_study_id>
    <nct_id>NCT03514420</nct_id>
  </id_info>
  <brief_title>Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL)</brief_title>
  <official_title>An Open-label Phase 2 Study of ISIS 703802 (AKCEA-ANGPTL3-LRx) Administered Subcutaneously to Subjects With Familial Partial Lipodystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akcea Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Akcea Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, open-label study to evaluate the efficacy of AKCEA-ANGPTL3-LRx for&#xD;
      reduction of fasting triglycerides in participants with familial partial lipodystrophy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2018</start_date>
  <completion_date type="Actual">August 21, 2019</completion_date>
  <primary_completion_date type="Actual">July 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Fasting Triglycerides Levels at End of the Treatment (Week 27)</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Area Under the Curve (AUC) of Plasma Glucose as Assessed by Mixed Meal Test (MMT) at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>Change from Baseline to Week 27 in the area under the curve (AUC) of Plasma Glucose was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in AUC of Serum Insulin as Assessed by MMT at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>Change from Baseline to Week 27 in the AUC of Serum Insulin was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in AUC of Serum C-peptide as Assessed by MMT at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>Change from Baseline to Week 27 in the AUC of Serum C-peptide was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in AUC of Free Fatty Acid (FFA) as Assessed by MMT at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>Change from Baseline to Week 27 in the AUC of FFA was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in AUC of Serum Ghrelin as Assessed by MMT at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>Change from Baseline to Week 27 in the AUC of Serum Ghrelin was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in AUC of Incretin Hormone (Gastric Inhibitory Polypeptide [GIP]) as Assessed by MMT at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>Change from Baseline to Week 27 in the AUC of Incretin Hormone: GIP was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in AUC of Incretin Hormone (Glucagon-like Peptide -1 [GLP-1]) as Assessed by MMT at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>Change from Baseline to Week 27 in the AUC of Incretin Hormone: GLP-1 was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in AUC of Peptide Tyrosine Tyrosine (PYY) as Assessed by MMT at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>Change from Baseline to Week 27 in the AUC of PYY was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HDL-C at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in LDL-C at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment. LDL-C calculated using ultracentrifugation method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Cholesterol (TC) at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in VLDL-C at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment. VLDL-C was calculated using direct test method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Non-HDL-C at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ApoB at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ApoB-48 at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Apolipoprotein B 100 (ApoB-100) at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ApoA-1 at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ApoC-III at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ApoC-III: Chylomicron at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ApoC-III: VLDL at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ApoC-III: LDL at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ApoC-III: HDL at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Lipoprotein a (Lp[a]) at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Free Fatty Acid (FFA) at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glycerol Levels at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Lipoprotein Particle Size at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>The baseline was defined as the Day 1 pre-dose fasting assessment. Lipoprotein Particle size included: HDL size, LDL size and VLDL size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hemoglobin A1c (HbA1c) at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>The baseline was defined as the last non-missing assessment prior to the first dose of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Homeostasis Model Assessment-Estimated Insulin Resistance (HOMA-IR)</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Adiponectin at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>The baseline was defined as the Day 1 pre-dose fasting assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in and Leptin at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>The baseline was defined as the Day 1 pre-dose fasting assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hepatic Fat Fraction (HFF) as Assessed by Magnetic Resonance Imaging (MRI) at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>The baseline was defined as the last non-missing assessment prior to the first dose of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline in Body Fat Distribution for Various Areas in the Body as Measured by Skinfold Thickness at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>The baseline was defined as the last assessment prior to the first dose of study drug. Change in body fat distribution was measured as right anterior thigh skinfold thickness and right tricep skinfold thickness by Skinfold Thickness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline in Body Fat Distribution for Various Areas in the Body as Measured by Dual-Energy X-ray Absorptiometry (DEXA) at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>The baseline was defined as the Screening assessment. Change in body fat distribution (arm bone mass, arm fat mass, arm lean mass, arm total mass, leg bone mass, leg fat mass, leg lean mass, leg total mass, total bone mass, total fat mass, total lean mass, total total mass , trunk bone mass, trunk fat mass, trunk lean mass and trunk total mass) was measures obtained from DEXA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline in Body Fat Distribution for Total Bone Mineral Density in the Body as Measured by Dual-Energy X-ray Absorptiometry (DEXA) at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>The baseline was defined as Screening assessment. Change in body fat distribution for total Bone mineral density was measures obtained from DEXA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Visceral Adipose Tissue (VAT) as Measured by Magnetic Resonance Imaging (MRI) at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>The baseline was defined as the last assessment prior to the first dose of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Subcutaneous Adipose Tissue (SAT) as MRI at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>The baseline was defined as the last assessment prior to the first dose of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>The baseline was defined as the Day 1 pre-dose assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Waist Circumference at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>The baseline was defined as the Screening assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Waist/Hip Ratio at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>The baseline was defined as screening assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Life (QoL)</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>The baseline was defined as the screening assessment. Quality of life measures the severity of fatigue, severity of trouble thinking or remembering and severity of waking up tired in participants, on a scale ranging from 0 to 3, where, 0= No problem, 1= Mild, 2= Moderate and 3= severe. Higher scores indicates more severity or more impact on quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pain Score at End of the Treatment</measure>
    <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
    <description>The baseline was defined as a Screening assessment. Pain score is used to determine disease activity in participants, on a scale ranging from 0 to 5 where 0= never, 1= hardly noticed, 2= slightly, 3= moderately, 4= strongly, and 5= very strongly where higher scores indicated higher degree of pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>From signing of informed consent to end of follow up period (Up to week 40)</time_frame>
    <description>An adverse event (AE) is any unfavorable and unintended sign (including a clinically-significant abnormal laboratory finding, for example), symptom, or disease temporally associated with the study or use of investigational drug product, whether or not the AE is considered related to the investigational drug product. &quot;A treatment-emergent adverse event (TEAE) is defined as any AE starting on or after the first dose of the study drug</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Familial Partial Lipodystrophy</condition>
  <arm_group>
    <arm_group_label>AKCEA-ANGPTL3-LRx 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received AKCEA-ANGPTL3-LRx 20 milligrams (mg) administered every week for 26 weeks by subcutaneous (SC) injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AKCEA-ANGPTL3-LRx</intervention_name>
    <description>AKCEA-ANGPTL3-LRx solution for SC injection.</description>
    <arm_group_label>AKCEA-ANGPTL3-LRx 20 mg</arm_group_label>
    <other_name>ISIS 703802</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Must give written informed consent to participate in the study.&#xD;
&#xD;
          -  Clinical diagnosis of familial partial lipodystrophy plus diagnosis of type 2 diabetes&#xD;
             mellitus and hypertriglyceridemia.&#xD;
&#xD;
          -  Diagnosis of diabetes mellitus, made at least 6 months prior to the Screening with&#xD;
             hemoglobin A1c (HbA1c) ≥ 7% to ≤ 12% at Screening and on anti-diabetic therapy as&#xD;
             defined in study protocol.&#xD;
&#xD;
          -  Hypertriglyceridemia as defined by fasting triglycerides (TG) levels ≥ 500 milligrams&#xD;
             per deciliter (mg/dL) at both Screening and Qualification visits. Participants with&#xD;
             the clinical diagnosis of FPL and with fasting TG levels ≥ 200 (≥ 2.26 millimoles per&#xD;
             liter [mmol/L]) to &lt; 500 mg/dL (≥ 5.7 mmol/L) who meet the genetic or family history&#xD;
             criteria for study inclusion may be further screened and enrolled in the study.&#xD;
&#xD;
          -  Presence of hepatosteatosis (fatty liver), as evidenced by a Screening magnetic&#xD;
             resonance imaging (MRI) indicating a hepatic fat fraction (HFF) ≥ 6.4%.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of generalized lipodystrophy.&#xD;
&#xD;
          -  Diagnosis of acquired partial lipodystrophy (APL).&#xD;
&#xD;
          -  Acute pancreatitis within 4 weeks of Screening.&#xD;
&#xD;
          -  Acute coronary syndrome within 6 months of Screening.&#xD;
&#xD;
          -  Major surgery within 3 months of Screening.&#xD;
&#xD;
          -  Have any other conditions in the opinion of the investigator which could interfere&#xD;
             with the participant participating in or completing the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 21, 2018</study_first_submitted>
  <study_first_submitted_qc>April 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2018</study_first_posted>
  <results_first_submitted>January 6, 2021</results_first_submitted>
  <results_first_submitted_qc>January 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 16, 2021</results_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lipodystrophy</keyword>
  <keyword>Lipodystrophy, Familial Partial</keyword>
  <keyword>Lipid Metabolism Disorders</keyword>
  <keyword>Dyslipidemias</keyword>
  <keyword>Kobberling-Dunnigan syndrome (type 1 and 2)</keyword>
  <keyword>Lipoatrophic Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lipodystrophy, Familial Partial</mesh_term>
    <mesh_term>Lipodystrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT03514420/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at a single center in the United States of America from 15 June 2018 to 21 August 2019.</recruitment_details>
      <pre_assignment_details>A total of 8 participants diagnosed with familial partial lipodystrophy (FPL) were screened, out of which 4 participants were treated with AKCEA-ANGPTL3-LRx 20 milligrams (mg). All 4 participants completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AKCEA-ANGPTL3-LRx 20 mg</title>
          <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by subcutaneous (SC) injection.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>AKCEA-ANGPTL3-LRx 20 mg</title>
          <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.3" spread="3.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Triglycerides (TG)</title>
          <units>milligram per deciliter (mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="817.8" spread="431.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Apolipoprotein B-48 (Apo B-48)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.109" spread="0.5588"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Apolipoprotein C-III (Apo CIII)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.435" spread="11.8481"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Apolipoprotein B (ApoB)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124.95" spread="24.972"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="223.4" spread="22.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting High Density Lipoprotein- Cholesterol (HDL-C)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.13" spread="3.473"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Apolipoprotein A-I (Apo A-1)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121.3" spread="9.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Very low Density Lipoprotein-Cholesterol (VLDL-C)</title>
          <description>VLDL-C calculated using direct test method.</description>
          <population>Number analyzed signifies the number of participants with data available for fasting VLDL-C.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130.3" spread="22.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Low Density Lipoprotein Cholesterol (LDL-C)</title>
          <description>LDL-C calculated using ultracentrifugation method.</description>
          <population>Number analyzed signifies the number of participants with data available for fasting LDL-C.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93.3" spread="24.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Area Under Curve (AUC) of Plasma Glucose</title>
          <units>milligram/deciliter*minute (mg/dL*min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="257" spread="45.2622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AUC of Serum Insulin</title>
          <units>milli international units/ liter*minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.625" spread="4.852748"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AUC of Serum C-peptide</title>
          <population>Number analyzed signifies the number of participants with data available for AUC of Serum C-peptide.</population>
          <units>nanogram/milliliter*minute (ng/mL*min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.266" spread="1.234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AUC of Free Fatty Acid</title>
          <population>Number analyzed signifies the number of participants with data available for AUC of Free fatty acid.</population>
          <units>milliequivalents/liter*min (mEq/L*min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.57" spread="0.458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AUC of Gastric Inhibitory Polypeptide (GIP)</title>
          <population>Number analyzed signifies the number of participants with data available for AUC of GIP.</population>
          <units>picograms/milliliter*minute (pg/mL*min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.02" spread="38.555"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AUC of Glucagon-like Peptide 1 (GLP-1)</title>
          <population>Number analyzed signifies the number of participants with data available for AUC of GLP-1.</population>
          <units>picomoles/liter*minute (pmol/L*min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.35" spread="17.065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AUC of Peptide Tyrosine Tyrosine (PYY)</title>
          <units>pg/mL*min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80.412" spread="99.559"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AUC of Serum Ghrelin</title>
          <units>pg/mL*min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.955" spread="15.127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Fasting Triglycerides Levels at End of the Treatment (Week 27)</title>
        <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Fasting Triglycerides Levels at End of the Treatment (Week 27)</title>
          <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-59.9" spread="26.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Area Under the Curve (AUC) of Plasma Glucose as Assessed by Mixed Meal Test (MMT) at End of the Treatment</title>
        <description>Change from Baseline to Week 27 in the area under the curve (AUC) of Plasma Glucose was assessed.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug. Here, Overall Number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Area Under the Curve (AUC) of Plasma Glucose as Assessed by Mixed Meal Test (MMT) at End of the Treatment</title>
          <description>Change from Baseline to Week 27 in the area under the curve (AUC) of Plasma Glucose was assessed.</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug. Here, Overall Number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>mg/dL*min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9815.0" spread="4071.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in AUC of Serum Insulin as Assessed by MMT at End of the Treatment</title>
        <description>Change from Baseline to Week 27 in the AUC of Serum Insulin was assessed.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug. Here, Overall Number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in AUC of Serum Insulin as Assessed by MMT at End of the Treatment</title>
          <description>Change from Baseline to Week 27 in the AUC of Serum Insulin was assessed.</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug. Here, Overall Number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>milli international units per liter*min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3262.0" spread="3775.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in AUC of Serum C-peptide as Assessed by MMT at End of the Treatment</title>
        <description>Change from Baseline to Week 27 in the AUC of Serum C-peptide was assessed.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug. Here, Overall Number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in AUC of Serum C-peptide as Assessed by MMT at End of the Treatment</title>
          <description>Change from Baseline to Week 27 in the AUC of Serum C-peptide was assessed.</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug. Here, Overall Number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>ng/mL*min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-192.3" spread="257.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in AUC of Free Fatty Acid (FFA) as Assessed by MMT at End of the Treatment</title>
        <description>Change from Baseline to Week 27 in the AUC of FFA was assessed.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug. Here, Overall Number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in AUC of Free Fatty Acid (FFA) as Assessed by MMT at End of the Treatment</title>
          <description>Change from Baseline to Week 27 in the AUC of FFA was assessed.</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug. Here, Overall Number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>mEq/L*min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-60.0" spread="42.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in AUC of Serum Ghrelin as Assessed by MMT at End of the Treatment</title>
        <description>Change from Baseline to Week 27 in the AUC of Serum Ghrelin was assessed.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug. Here, Overall Number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in AUC of Serum Ghrelin as Assessed by MMT at End of the Treatment</title>
          <description>Change from Baseline to Week 27 in the AUC of Serum Ghrelin was assessed.</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug. Here, Overall Number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>pg/mL*min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8479.5" spread="7241.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in AUC of Incretin Hormone (Gastric Inhibitory Polypeptide [GIP]) as Assessed by MMT at End of the Treatment</title>
        <description>Change from Baseline to Week 27 in the AUC of Incretin Hormone: GIP was assessed.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug. Here, Overall Number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in AUC of Incretin Hormone (Gastric Inhibitory Polypeptide [GIP]) as Assessed by MMT at End of the Treatment</title>
          <description>Change from Baseline to Week 27 in the AUC of Incretin Hormone: GIP was assessed.</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug. Here, Overall Number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>pg/mL*min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1694.7" spread="11752.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in AUC of Incretin Hormone (Glucagon-like Peptide -1 [GLP-1]) as Assessed by MMT at End of the Treatment</title>
        <description>Change from Baseline to Week 27 in the AUC of Incretin Hormone: GLP-1 was assessed.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug. Here, Overall Number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in AUC of Incretin Hormone (Glucagon-like Peptide -1 [GLP-1]) as Assessed by MMT at End of the Treatment</title>
          <description>Change from Baseline to Week 27 in the AUC of Incretin Hormone: GLP-1 was assessed.</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug. Here, Overall Number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>pmol/L*min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1677.3" spread="11301.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in AUC of Peptide Tyrosine Tyrosine (PYY) as Assessed by MMT at End of the Treatment</title>
        <description>Change from Baseline to Week 27 in the AUC of PYY was assessed.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug. Here, Overall Number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in AUC of Peptide Tyrosine Tyrosine (PYY) as Assessed by MMT at End of the Treatment</title>
          <description>Change from Baseline to Week 27 in the AUC of PYY was assessed.</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug. Here, Overall Number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>pg/mL*min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6549.0" spread="10632.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HDL-C at End of the Treatment</title>
        <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HDL-C at End of the Treatment</title>
          <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="6.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in LDL-C at End of the Treatment</title>
        <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment. LDL-C calculated using ultracentrifugation method.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug. Here, Overall Number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LDL-C at End of the Treatment</title>
          <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment. LDL-C calculated using ultracentrifugation method.</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug. Here, Overall Number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" spread="NA">Due to a single analyzed participant, standard deviation was not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Cholesterol (TC) at End of the Treatment</title>
        <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Cholesterol (TC) at End of the Treatment</title>
          <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.3" spread="32.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in VLDL-C at End of the Treatment</title>
        <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment. VLDL-C was calculated using direct test method.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug. Here, Overall Number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in VLDL-C at End of the Treatment</title>
          <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment. VLDL-C was calculated using direct test method.</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug. Here, Overall Number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.0" spread="NA">Due to a single analyzed participant, standard deviation was not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Non-HDL-C at End of the Treatment</title>
        <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Non-HDL-C at End of the Treatment</title>
          <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.4" spread="34.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ApoB at End of the Treatment</title>
        <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ApoB at End of the Treatment</title>
          <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="25.265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ApoB-48 at End of the Treatment</title>
        <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ApoB-48 at End of the Treatment</title>
          <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.601" spread="1.3284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Apolipoprotein B 100 (ApoB-100) at End of the Treatment</title>
        <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Apolipoprotein B 100 (ApoB-100) at End of the Treatment</title>
          <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.433" spread="24.6001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ApoA-1 at End of the Treatment</title>
        <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ApoA-1 at End of the Treatment</title>
          <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.8" spread="22.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ApoC-III at End of the Treatment</title>
        <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ApoC-III at End of the Treatment</title>
          <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.555" spread="9.1220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ApoC-III: Chylomicron at End of the Treatment</title>
        <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Data is not available as the collected Baseline samples were not sufficient to assess this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ApoC-III: Chylomicron at End of the Treatment</title>
          <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
          <population>Data is not available as the collected Baseline samples were not sufficient to assess this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ApoC-III: VLDL at End of the Treatment</title>
        <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Data is not available as the collected Baseline samples were not sufficient to assess this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ApoC-III: VLDL at End of the Treatment</title>
          <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
          <population>Data is not available as the collected Baseline samples were not sufficient to assess this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ApoC-III: LDL at End of the Treatment</title>
        <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug. Here, Overall Number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ApoC-III: LDL at End of the Treatment</title>
          <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug. Here, Overall Number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.110" spread="NA">Due to a single analyzed participant, standard deviation was not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ApoC-III: HDL at End of the Treatment</title>
        <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ApoC-III: HDL at End of the Treatment</title>
          <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.904" spread="5.9174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Lipoprotein a (Lp[a]) at End of the Treatment</title>
        <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Lipoprotein a (Lp[a]) at End of the Treatment</title>
          <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
          <units>nanomoles per liter (nmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" spread="14.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Free Fatty Acid (FFA) at End of the Treatment</title>
        <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Free Fatty Acid (FFA) at End of the Treatment</title>
          <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
          <units>millimoles per liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5779" spread="0.8778"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Glycerol Levels at End of the Treatment</title>
        <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycerol Levels at End of the Treatment</title>
          <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
          <units>micromoles per liter (μmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.0" spread="3.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Lipoprotein Particle Size at End of the Treatment</title>
        <description>The baseline was defined as the Day 1 pre-dose fasting assessment. Lipoprotein Particle size included: HDL size, LDL size and VLDL size.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Lipoprotein Particle Size at End of the Treatment</title>
          <description>The baseline was defined as the Day 1 pre-dose fasting assessment. Lipoprotein Particle size included: HDL size, LDL size and VLDL size.</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
          <units>nanometer (nm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HDL Size</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Size</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VLDL Size</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.7" spread="7.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hemoglobin A1c (HbA1c) at End of the Treatment</title>
        <description>The baseline was defined as the last non-missing assessment prior to the first dose of study drug.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin A1c (HbA1c) at End of the Treatment</title>
          <description>The baseline was defined as the last non-missing assessment prior to the first dose of study drug.</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
          <units>percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="0.991"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Homeostasis Model Assessment-Estimated Insulin Resistance (HOMA-IR)</title>
        <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Due to the low number of participants, data for this outcome measure was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Homeostasis Model Assessment-Estimated Insulin Resistance (HOMA-IR)</title>
          <description>The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.</description>
          <population>Due to the low number of participants, data for this outcome measure was not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Adiponectin at End of the Treatment</title>
        <description>The baseline was defined as the Day 1 pre-dose fasting assessment.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Adiponectin at End of the Treatment</title>
          <description>The baseline was defined as the Day 1 pre-dose fasting assessment.</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
          <units>microgram per milliliter (µg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.742"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in and Leptin at End of the Treatment</title>
        <description>The baseline was defined as the Day 1 pre-dose fasting assessment</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in and Leptin at End of the Treatment</title>
          <description>The baseline was defined as the Day 1 pre-dose fasting assessment</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="2.650"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hepatic Fat Fraction (HFF) as Assessed by Magnetic Resonance Imaging (MRI) at End of the Treatment</title>
        <description>The baseline was defined as the last non-missing assessment prior to the first dose of study drug.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hepatic Fat Fraction (HFF) as Assessed by Magnetic Resonance Imaging (MRI) at End of the Treatment</title>
          <description>The baseline was defined as the last non-missing assessment prior to the first dose of study drug.</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
          <units>percentage of hepatic fat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1400" spread="6.1107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline in Body Fat Distribution for Various Areas in the Body as Measured by Skinfold Thickness at End of the Treatment</title>
        <description>The baseline was defined as the last assessment prior to the first dose of study drug. Change in body fat distribution was measured as right anterior thigh skinfold thickness and right tricep skinfold thickness by Skinfold Thickness.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline in Body Fat Distribution for Various Areas in the Body as Measured by Skinfold Thickness at End of the Treatment</title>
          <description>The baseline was defined as the last assessment prior to the first dose of study drug. Change in body fat distribution was measured as right anterior thigh skinfold thickness and right tricep skinfold thickness by Skinfold Thickness.</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
          <units>millimeter (mm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Right Anterior Thigh Skinfold Thickness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="2.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Tricep Skinfold Thickness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="3.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline in Body Fat Distribution for Various Areas in the Body as Measured by Dual-Energy X-ray Absorptiometry (DEXA) at End of the Treatment</title>
        <description>The baseline was defined as the Screening assessment. Change in body fat distribution (arm bone mass, arm fat mass, arm lean mass, arm total mass, leg bone mass, leg fat mass, leg lean mass, leg total mass, total bone mass, total fat mass, total lean mass, total total mass , trunk bone mass, trunk fat mass, trunk lean mass and trunk total mass) was measures obtained from DEXA.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline in Body Fat Distribution for Various Areas in the Body as Measured by Dual-Energy X-ray Absorptiometry (DEXA) at End of the Treatment</title>
          <description>The baseline was defined as the Screening assessment. Change in body fat distribution (arm bone mass, arm fat mass, arm lean mass, arm total mass, leg bone mass, leg fat mass, leg lean mass, leg total mass, total bone mass, total fat mass, total lean mass, total total mass , trunk bone mass, trunk fat mass, trunk lean mass and trunk total mass) was measures obtained from DEXA.</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
          <units>gram (g)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Arm Bone Mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" spread="19.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm Fat Mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="603.8" spread="803.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm Lean Mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="273.3" spread="612.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm Total Mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="875.0" spread="1384.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg Bone Mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" spread="40.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg Fat Mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="436.8" spread="662.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg Lean Mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-345.8" spread="1384.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg Total Mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.0" spread="1736.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bone Mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.3" spread="77.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Fat Mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1197.3" spread="1667.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Lean Mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-891.5" spread="1852.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Total Mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="350.0" spread="3183.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trunk Bone Mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" spread="35.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trunk Fat Mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183.5" spread="296.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trunk Lean Mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-728.8" spread="590.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trunk Total Mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-500.0" spread="836.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline in Body Fat Distribution for Total Bone Mineral Density in the Body as Measured by Dual-Energy X-ray Absorptiometry (DEXA) at End of the Treatment</title>
        <description>The baseline was defined as Screening assessment. Change in body fat distribution for total Bone mineral density was measures obtained from DEXA.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline in Body Fat Distribution for Total Bone Mineral Density in the Body as Measured by Dual-Energy X-ray Absorptiometry (DEXA) at End of the Treatment</title>
          <description>The baseline was defined as Screening assessment. Change in body fat distribution for total Bone mineral density was measures obtained from DEXA.</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
          <units>gram per centimeter square (g/cm^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Visceral Adipose Tissue (VAT) as Measured by Magnetic Resonance Imaging (MRI) at End of the Treatment</title>
        <description>The baseline was defined as the last assessment prior to the first dose of study drug.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Due to the low number of participants, data for this outcome measure was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Visceral Adipose Tissue (VAT) as Measured by Magnetic Resonance Imaging (MRI) at End of the Treatment</title>
          <description>The baseline was defined as the last assessment prior to the first dose of study drug.</description>
          <population>Due to the low number of participants, data for this outcome measure was not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Subcutaneous Adipose Tissue (SAT) as MRI at End of the Treatment</title>
        <description>The baseline was defined as the last assessment prior to the first dose of study drug.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Due to the low number of participants, data for this outcome measure was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Subcutaneous Adipose Tissue (SAT) as MRI at End of the Treatment</title>
          <description>The baseline was defined as the last assessment prior to the first dose of study drug.</description>
          <population>Due to the low number of participants, data for this outcome measure was not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight at End of the Treatment</title>
        <description>The baseline was defined as the Day 1 pre-dose assessment.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight at End of the Treatment</title>
          <description>The baseline was defined as the Day 1 pre-dose assessment.</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.05" spread="3.309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Waist Circumference at End of the Treatment</title>
        <description>The baseline was defined as the Screening assessment.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Waist Circumference at End of the Treatment</title>
          <description>The baseline was defined as the Screening assessment.</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.88" spread="1.863"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Waist/Hip Ratio at End of the Treatment</title>
        <description>The baseline was defined as screening assessment.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Due to the low number of participants, data for this outcome measure was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Waist/Hip Ratio at End of the Treatment</title>
          <description>The baseline was defined as screening assessment.</description>
          <population>Due to the low number of participants, data for this outcome measure was not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Quality of Life (QoL)</title>
        <description>The baseline was defined as the screening assessment. Quality of life measures the severity of fatigue, severity of trouble thinking or remembering and severity of waking up tired in participants, on a scale ranging from 0 to 3, where, 0= No problem, 1= Mild, 2= Moderate and 3= severe. Higher scores indicates more severity or more impact on quality of life.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quality of Life (QoL)</title>
          <description>The baseline was defined as the screening assessment. Quality of life measures the severity of fatigue, severity of trouble thinking or remembering and severity of waking up tired in participants, on a scale ranging from 0 to 3, where, 0= No problem, 1= Mild, 2= Moderate and 3= severe. Higher scores indicates more severity or more impact on quality of life.</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Severity of fatigue</title>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity of trouble thinking or remembering</title>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity of waking up tired</title>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pain Score at End of the Treatment</title>
        <description>The baseline was defined as a Screening assessment. Pain score is used to determine disease activity in participants, on a scale ranging from 0 to 5 where 0= never, 1= hardly noticed, 2= slightly, 3= moderately, 4= strongly, and 5= very strongly where higher scores indicated higher degree of pain.</description>
        <time_frame>Baseline and End of the Treatment (Week 27)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pain Score at End of the Treatment</title>
          <description>The baseline was defined as a Screening assessment. Pain score is used to determine disease activity in participants, on a scale ranging from 0 to 5 where 0= never, 1= hardly noticed, 2= slightly, 3= moderately, 4= strongly, and 5= very strongly where higher scores indicated higher degree of pain.</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="3.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-emergent Adverse Events (TEAEs)</title>
        <description>An adverse event (AE) is any unfavorable and unintended sign (including a clinically-significant abnormal laboratory finding, for example), symptom, or disease temporally associated with the study or use of investigational drug product, whether or not the AE is considered related to the investigational drug product. &quot;A treatment-emergent adverse event (TEAE) is defined as any AE starting on or after the first dose of the study drug</description>
        <time_frame>From signing of informed consent to end of follow up period (Up to week 40)</time_frame>
        <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>AKCEA-ANGPTL3-LRx 20 mg</title>
            <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Adverse Events (TEAEs)</title>
          <description>An adverse event (AE) is any unfavorable and unintended sign (including a clinically-significant abnormal laboratory finding, for example), symptom, or disease temporally associated with the study or use of investigational drug product, whether or not the AE is considered related to the investigational drug product. &quot;A treatment-emergent adverse event (TEAE) is defined as any AE starting on or after the first dose of the study drug</description>
          <population>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From signing of informed consent to end of follow up period (Up to week 40)</time_frame>
      <desc>Safety set included all participants who were enrolled and received at least 1 dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>AKCEA-ANGPTL3-LRx 20 mg</title>
          <description>Participants received AKCEA-ANGPTL3-LRx 20 mg administered every week for 26 weeks by subcutaneous (SC) injection.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (20.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site dryness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Albumin urine present</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Antinuclear antibody positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Blood magnesium decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Creatinine urine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Glycosylated haemoglobin increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Insulin C-peptide decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Urine albumin/creatinine ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>urinary casts</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Mean cell haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Mean cell volume decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Blood calcium decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Crystal urine present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Liver function test</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Akcea Therapeutics</organization>
      <phone>617-207-0289</phone>
      <email>clinicalstudies@akceatx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

